Ongoing ERT clinical trials in adults with ENPP1 (ARHR2) and ABCC6 deficiency (pseudoxanthoma elasticum) demonstrate that subcutaneous ENPP1 administration restores physiological PPi levels in these patients, with a dose-response unique to the underlying genetic deficiency (https://investors.inozyme.com/events-presentations). The gene discussed is ENPP1; the disease is hyperinsulinemic hypoglycemia, familial, 4.